Research article · 29 Aug 2017
Conference abstractPublished 23 Nov 2012
Quality-by-design approach to analytical method development
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Quality-by-design was first described by Joseph M. Juran, is a systematic approach to drug development, which begins with pre-defined objectives, and uses science and risk management approaches to gain product and process understanding and ultimately process control. The FDA has recently begun to advocate the QbD methodology for the pharmaceutical sector. More companies in the pharmaceutical industry today are in the need of adopting the principles of Quality-by-design (QbD) to the development of analytical methods in addition to the development of manufacturing processes. As such, both industry and regulators recognize the benefits of adopting a QbD approach to drug-product development and manufacture, with key concepts described in the International Conference on Harmonization (ICH) guidelines, Q8 (R1) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. Drug development using the principles of QbD can be introduced as two key concepts that further aid in implementation. The first concept is the ?design space? that generally involves the identification of the critical attributes for the input materials, the process, and the final product. Another important concept is that of the ?control strategy? which is to ensure the final quality of the product. Some of the concepts are more applicable than others, and some have been advocated by many method development experts for some time, but modern technology has created an opportunity to revisit strategies for creation of chromatographic methods in particular, and it is certainly interesting to investigate the new opportunities in the context of Quality by Design. The ultimate goal is to highlight the QbD concepts and terminology can be applied to analytical methods and to suggest how adoption of a QbD approach might be used to develop more robust analytical methods and effective control systems.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Quality-by-design approach for formulation development of drug nanoparticles
Research article · 27 Feb 2021
Quality-by-Design Based Development and Validation of Stability Indicating Method by UPLC Method for Impurities of Simvastatin from Drug and Pharmaceutical Dosage Form
Research article · 28 Sep 2023
Implementation of Quality by Design Approach to Analytical Method Development and Validation for Estimation of Morniflumate Pharmaceutical Dosage Form
Research article · 3 May 2019
Analytical Quality by Design (QbD) Approach to RP-HPLC Method Development and Validation of Meloxicam
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Yogita Prajapati”

